Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Adlai Nortye Ltd.NASDAQ: ANL

EBITDA · Q2 FY2024 · quarter ended Jun 2024

EBITDA remains negative

Q2 FY2024 EBITDA was -$14.36M, compared with -$62.58M a year earlier. Trailing-twelve-month EBITDA was -$63.57M.

Context

  • EBITDA amounted to 652.5% of revenue in FY2025.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $616.53K (+101.9%) for the fiscal year ending Dec 2026, a step up from the +32.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2024
-$14.36M+0.0% QoQ
Last fiscal yearDec 2025
-$32.63M+32.1% YoY
LTMJun 2024
-$63.57M+44.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+77.1%+100.8%+23.7 pp
1 year+32.1%+101.9%+69.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(32.63M) USD
Year-over-year change
+32.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's LTM Jun 2024 EBITDA of -$63.57M is the 4th highest of the 7 companies compared; the peer median is -$57.4M.
  • EBITDA amounts to 979.5% of revenue for ANL, versus a peer median of 108.4%.
ANL Competitors Peer median
EBITDA for ANL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M +463.6%—48.0%
APLMApollomics, Inc.FY2025-$9.22M +77.5%—108.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M -2.3%——
ANLAdlai Nortye Ltd.LTM Jun 2024-$63.57M ——979.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$72.53M +7.7%—257.0%
NUVBNuvation Bio Inc.LTM Jun 2026-$127.04M +36.8%—74.8%
VSTMVerastem, Inc.LTM Mar 2026-$191.95M -32.3%—387.1%
Peer median (excluding ANL) -$57.4M+22.3%—108.4%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.73M0005M
Cost of Revenue00000
Gross Profit45.73M0005M
Gross Margin100.0%———100.0%
Research & Development42.11M54.49M58.15M44.92M32.83M
Selling, General & Admin12.45M12.43M14.82M9.44M7.79M
Operating Expenses54.37M67.27M72.55M52.93M40.7M
Depreciation & Amortization1.83M2.04M2.22M1.87M1.41M
EBITDA(53.51M)(56.32M)(106.22M)(48.06M)(32.63M)
EBITDA Margin-117.0%———-652.5%
Operating Income(8.65M)(67.27M)(72.55M)(52.93M)(35.7M)
Operating Margin-18.9%———-714.0%
Interest Income32K550K62K01K
Interest Expense1.34M433K791K1.94M1.49M
Other Income / Expenses(48.03M)8.48M(36.68M)1.06M170K
Income Before Tax(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Pre-Tax Margin-124.0%———-710.6%
Income Tax Expense00000
Net Income(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Net Margin-124.0%———-710.6%
EPS (Basic)(6.66)(6.93)(15.42)(4.89)(3.33)
EPS (Diluted)(6.66)(6.93)(15.42)(4.89)(3.33)
Weighted Avg Shares8.48M8.48M6.8M10.64M10.66M
Weighted Avg Shares (Diluted)8.48M8.48M6.8M10.64M10.66M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.